Cognia to create operations and development center in Scotland.

Cognia, a database specialist for the pharmaceutical and biotechnology industries, has announced its plans to create a new operations center in Edinburgh. The new center will be responsible for commercializing and deploying text mining systems that help PhD-level curators analyze large quantities of scientific text to identify and extract valuable information.
Register for free to listen to this article
Listen with Speechify
0:00
2:00
EDINBURGH, Scotland—Cognia, a database specialist for the pharmaceutical and biotechnology industries, has announced its plans to create a new operations center in Edinburgh. The new center will be responsible for commercializing and deploying text mining systems that help PhD-level curators analyze large quantities of scientific text to identify and extract valuable information. The company's 30-person development center already had been operating in Edinburgh since March 2005, and the expansion and addition of operations center staff is expected to more than triple that total.
Continue reading below...
A black mosquito is shown on pink human skin against a blurred green backdrop.
InfographicsDiscovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Read More
"Cognia is extremely excited that we can place our entire development and operations centers in a single facility in Scotland," says Cognia CEO Robert Merold. "Scotland has a world-class work force and is a leader in both life science and natural language processing. The high caliber of technologists and scientists working in Scotland also allows Cognia to deliver our truly unique products to the market with the flexibility that the industry demands."
The company has also recently signed a commercial license agreement with Intermediary Technology Institute (ITI) Life Sciences in Scotland to develop in-license text mining intellectual property in a program with Cognia and Edinburgh University's School of Informatics. ITI Life Sciences is a publicly funded, commercially driven organization that funds and manages early-stage technology research and development programs in the life sciences arena.
"More effective and efficient drug discovery and development is based on speeding up the often complex research processes, including sorting through volumes of previous studies and results. Scotland's world renowned expertise in text mining and informatics will contribute significantly to the development of commercialized technologies in this field," notes Lorna Jack, president of the Americas for the organization Scottish Development International, which works to attract inward investment and knowledge to Scotland and helps Scottish companies do more business overseas. "The country's role as an innovator in the life sciences industry, along with its highly skilled work force, is a major attraction for leading companies, such as Cognia. Cognia's partnership with the University of Edinburgh and ITI Life Sciences has also enabled Scotland to further expand its life sciences capabilities, and we anticipate that this technology will soon be transferred to other sectors."
Cognia's investment in Scotland has been supported by a grant of more than $1.5 million from the Scottish Executive and is expected to result in approximately 75 new "high-value" jobs.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Fluorescent-style illustration of spherical embryonic stem cells clustered together against a dark background.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes. 
3D illustration of ciliated cells, with cilia shown in blue.
Ultraprecise proteomic analysis reveals new insights into the molecular machinery of cilia.
3D illustration showing a DNA double helix encapsulated in a transparent capsule, surrounded by abstract white and orange protein-like molecular structures against a blue background.
Discover an integrated analytical approach that unites identification, purification, and stability assessment for therapeutic molecules.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue